Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
This systematic review evaluates cannabinoid efficacy dementia symptoms including agitation, anxiety, and depression in patients with dementia. It highlights cannabinoids as a potential safer alternative to traditional antipsychotics. The study…
GLP-1 Receptor Agonist Cardiovascular Evidence: Meta-Analysis
This GLP-1 receptor agonist cardiovascular meta-analysis synthesizes data from major trials demonstrating reduced cardiovascular events. The evidence supports GLP-1 receptor agonists as cardioprotective agents beyond weight loss. Clinicians can use this…
Strategies for Muscle Preservation During GLP-1 Therapy
Muscle preservation during GLP-1 receptor agonist therapy is critical to avoid excessive lean mass loss. This page discusses strategies to maintain muscle while benefiting from GLP-1 treatments. Clinicians should emphasize resistance training and…
Efficacy of high-definition transcranial direct current stimulation on craving in substance use disorders: a systematic review and meta-analysis.
High-definition transcranial direct current stimulation is a promising noninvasive method for reducing craving in substance use disorders. This systematic review and meta-analysis evaluates its efficacy. The focus on craving highlights its potential role…
Cannabis Use and Trauma-Focused Treatment for PTSD: Meta-Analysis
Cannabis trauma-focused treatment PTSD research reveals that cannabis use does not diminish the effectiveness of evidence-based PTSD therapies. Individuals with PTSD and substance use disorders benefit from trauma-focused treatments regardless of…
Review of Cannabinoid Clinical Trials for Mental Disorders Safety
This cannabinoid clinical trials mental disorders safety review examines randomized controlled trials assessing efficacy and safety. Evidence remains limited and inconclusive for cannabinoids as treatments. Clinicians should interpret claims cautiously…
GLP-1 Receptor Agonist Randomized Trial: Muscle Loss Risk
GLP-1 receptor agonist muscle mass loss is a significant concern in obesity treatment. Randomized trials show these agents can cause disproportionate lean muscle loss. Clinicians should emphasize muscle preservation strategies alongside therapy.
Comparing Muscle Loss Risks with GLP-1 Receptor Agonists
GLP-1 receptor agonist muscle loss compared to other weight loss methods reveals important risks. Semaglutide and liraglutide cause significant weight loss but may reduce lean muscle mass. Understanding these risks helps optimize treatment and preserve…
Over 70% Of Studies Back Medical Cannabis In Cancer Treatment: A Sweeping Meta-Analysis
A medical cannabis cancer treatment meta-analysis found that over 70% of studies demonstrate clinical benefit. This meta-analysis supports cannabis use in oncology for symptom management. The findings highlight cannabis's role in cancer supportive care.
Review of Cannabinoid Clinical Trials for Anxiety and Tourette
Cannabinoid clinical trials anxiety research reveals measurable reductions in anxiety symptoms across various disorders. Evidence supports modest but meaningful benefits, especially for generalized anxiety and Tourette syndrome. These findings highlight…